Have a personal or library account? Click to login
Parathyroidectomy in a patient treated with emicizumab Cover

Parathyroidectomy in a patient treated with emicizumab

The Journal of Haemophilia Practice
Volume 6 (2019): Issue 1 (January 2019)
By: Helen Hupston  
Open Access
|Dec 2019

Figures & Tables

A patient with haemophilia A and inhibitors undergoing parathyroidectomy continued a standard maintenance dose of emicizumab, with bleed risk managed intra- and postoperatively with recombinant Factor VIIa (rFVIIa) and tranexamic acid. Despite the risk of hypercoagulability with the combination of emicizumab and rFVIIa, no postoperative complications were reported.© Shutterstock
A patient with haemophilia A and inhibitors undergoing parathyroidectomy continued a standard maintenance dose of emicizumab, with bleed risk managed intra- and postoperatively with recombinant Factor VIIa (rFVIIa) and tranexamic acid. Despite the risk of hypercoagulability with the combination of emicizumab and rFVIIa, no postoperative complications were reported.© Shutterstock
DOI: https://doi.org/10.17225/jhp00149 | Journal eISSN: 2055-3390
Journal RSS Feed
Language: English
Page range: 51 - 53
Published on: Dec 23, 2019
Published by: Haemnet Ltd
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Emicizumab,
surgery,
Factor VIIa,
tranexamic acid,
parathyroidectomy
Related subjects:
Medicine,
Basic medical science,
Basic medical science, other,
Clinical medicine,
Clinical medicine, other,
Pharmacy,
Pharmacology

© 2019 Helen Hupston, published by Haemnet Ltd
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 6 (2019): Issue 1 (January 2019)Next article